Edition:
United Kingdom

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

11.31EUR
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
€11.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
109,318
52-wk High
€14.08
52-wk Low
€9.01

Latest Key Developments (Source: Significant Developments)

Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests
Monday, 4 Dec 2017 

Dec 4 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS AND AMGEN <<>> SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS.BIOCARTIS -WILL PURSUE A PREMARKET APPROVAL FOR IDYLLA KRAS MUTATION TEST AND IDYLLA NRAS-BRAF MUTATION TEST WITH FDA​.‍AMGEN WILL PROVIDE FINANCIAL AND OPERATIONAL SUPPORT TO BIOCARTIS FOR PMA PROCESS​.‍AIM OF AGREEMENT IS TO REGISTER IDYLLA RAS BIOMARKER TESTS WITH US FDA AS COMPANION DIAGNOSTIC TEST FOR AMGEN'S DRUG VECTIBIX(PANITUMUMAB).​.  Full Article

Bookrunner says Biocartis Group deal upsized to 80 mln euros From 60 mln euros base deal size‍​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - :BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS DEAL UPSIZED TO 80 MILLION EUROS FROM 60 MILLION EUROS BASE DEAL SIZE‍​.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS ARE OVERSUBSCRIBED ON THE 80 MILLION EUROS DEAL SIZE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS PRICE GUIDANCE OF 12.50 EUROS PER SHARE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS CLOSE AT 1830 UK TIME.  Full Article

Biocartis Share Offering Of Up To About 8.9 mln Shares ‍​- bookrunner
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Biocartis Group Nv's Bookrunner: :SAYS OFFERING OF UP TO ABOUT 8.9 MILLION SHARES ‍​.SAYS OFFERING DEAL SIZE ABOUT 60 MILLION EUROS‍​.  Full Article

Biocartis Launches Equity Placement
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT.‍EQUITY OFFERING TO RAISE AN AMOUNT OF APPROXIMATELY EUR 60 MILLION BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING​.‍POSSIBILITY TO INCREASE SIZE OF OFFERING TO UP TO 8,933,950 NEW SHARES IN TOTAL​.‍BOOKBUILDING PROCEDURE WILL COMMENCE IMMEDIATELY​.‍TRADING IN BIOCARTIS SHARES ON EURONEXT BRUSSELS WILL BE SUSPENDED DURING BOOKBUILDING PERIOD​.‍J.P. MORGAN, DEGROOF PETERCAM, KBC SECURITIES AND KEMPEN ARE ACTING AS JOINT BOOKRUNNERS IN OFFERING​.‍ENVISAGES USING NET PROCEEDS TO FUND EXPANSION OF IDYLLA TEST MENU AND APPLICATIONS​.‍TRADING IN STOCK IS EXPECTED TO RESUME FOLLOWING PUBLICATION OF RESULTS OF OFFERING​.  Full Article

Biocartis Group sees ‍2017 guidance reiterated
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - BIOCARTIS GROUP NV ::SEES ‍2017 GUIDANCE REITERATED​.‍CASH POSITION AT END OF Q3 2017 AMOUNTED TO APPROXIMATELY EUR 56 MILLION (UNAUDITED FIGURE)​.  Full Article

Biocartis and A*Star's ETPL initiate development of breast cancer assay
Monday, 10 Jul 2017 

July 10 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS AND A*STAR'S ETPL INITIATE DEVELOPMENT OF BREAST CANCER ASSAY TO GUIDE THERAPY SELECTION.  Full Article

Biocartis Group H1 net loss widens to 23.8 million euros
Tuesday, 6 Sep 2016 

Biocartis Group NV : Cash and cash equivalents at the end of H1 75.8 million euros ($84.49 million) versus 128.5 million euros year ago . H1 net loss 23.8 million euros versus loss of 16.9 million euros year ago . H1 operational loss 24.0 million euros versus loss of 16.8 million euros year ago . Following the H1 2016 performance, guidance for the installed base expansion is increased to the top end of the 150-175 range . Guidance for launching at least four new tests in 2016 reiterated . Ce-Marking of Idylla(TM) NRAS mutation test and Idylla(TM)NRAS-BRAF mutation test solid biopsy tests expected in H2 . US FDA 510k submissions for the Idylla(TM) respiratory (IFV-RSV) panel and the Idylla(TM) instrument and Idylla(TM) console expected in H2 . Guidance on target cash position by end 2016 in the range of 45 million euros to 55 million euros reiterated .H1 total operating income 6.8 million euros versus 7.2 million euros year ago.  Full Article

Biocartis Group's Ebola test granted emergency use authorization by FDA
Wednesday, 1 Jun 2016 

Biocartis Group NV :Idylla Ebola virus triage test granted emergency use authorization by U.S. FDA.  Full Article

Biocartis reiterates guidance for 2016
Thursday, 12 May 2016 

Biocartis Group NV : Cash position end of Q1 2016 amounted to about 84 million euro ($95.9 million) . Guidance for 2016 reiterated . On track to complete critical mass of solid biopsy testing for oncology in H1 2016 with the planned launch of a solid biopsy lung cancer panel in Q2 2016 .Installed base growth progressed further in Q1 2016 and is on track to realise target of adding 150-175 idylla instruments in 2016.  Full Article

Biocartis and Amgen collaborate on rapid RAS biomarker testing
Wednesday, 3 Feb 2016 

Biocartis group NV:Biocartis and Amgen collaborate to offer rapid RAS biomarker testing to selected hospitals and clinics in Brazil, Canada, Colombia, Mexico, Saudi Arabia, Spain and Turkey.‍Biocartis and Amgen have entered into a collaboration to evaluate Idylla RAS testing as tool for rapid decentralized testing​.  Full Article

BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests

* BIOCARTIS AND AMGEN SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS